A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Tarsus Pharmaceuticals, Inc. · NCT07886268
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 32
- US sites recruiting
- 4
- Study start
- April 20, 2026
- Record last updated
- October 21, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess corneal healing and safety.
Being studied: TP-06; Vehicle of TP-06
Conditions: Persistent Corneal Epithelial Defect
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Able and willing to provide written informed consent
- Presence of a non-infected persistent corneal epithelial defect (PCED) in one eye that has failed to heal after at least 10 days of appropriate standard-of-care treatment
- Stable lesion size between Screening and Baseline as assessed by the Investigator
Exclusion Criteria
- Active ocular infection in either eye
- Corneal perforation or high risk of corneal perforation
- Severe eyelid abnormalities
- Ocular or eyelid surgery in the study eye within 3 months prior to Baseline (unless PCED was caused by surgery)
- Use of prohibited ophthalmic medications or procedures as defined in the protocol
- Any condition that, in the Investigator's judgment, would interfere with study participation or interpretation of results
Note: Additional exclusion criteria apply, as defined in the protocol
Recruiting US locations
Tarsus Investigative Site
Atlanta, GA 30339
Tarsus Investigative Site
Alexandria, MN 56308
Tarsus Investigative Site
Houston, TX 77008
Tarsus Investigative Site
Sugar Land, TX 77478
Study contacts (from the official record)
- Study Director · 888-421-4002 · clinical@tarsusrx.com
- Study Coordinator · 888-421-4002